President Donald Trump’s pick for U.S. drug czar withdrew after it become public that he spearheaded a bill that undercut the government’s power to crack down on opioid makers that were flooding the market with the addictive painkillers.
Hours before the U.S. Senate recessed for the remainder of summer 2017, legislators approved key legislation that will provide the necessary funding to keep the U.S. FDA operating efficiently.
Republican and Democratic lawmakers discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines.
By Susan Cornwell WASHINGTON (Reuters) – U.S. Senate Republicans will vote on a straight repeal of Obamacare after efforts to overhaul the law collapsed, rattling financial markets on Tuesday and clouding the path forward for President Donald Trump’s other domestic policy goals. After two Republicans said they would not back the latest Obamacare […]
A potentially lengthy U.S. legislative fight over replacement of the Obamacare health law got underway as two House of Representatives committees begin negotiating over changes to a Republican plan backed by President Donald Trump.
A U.S. House of Representatives subcommittee will take up bipartisan legislation to spur generic drug development, the committee’s chairman said.
Executives from the 2015 and 2014 Manny Award winners and finalists share their views on a variety of industry-related topics.
Democratic presidential candidate Hillary Clinton will unveil a plan this week to cap out-of-pocket costs for specialty drugs, her campaign said on Monday, as a tweet from Clinton accusing companies of “price gouging” sent biotech stocks tumbling. Clinton was expected to allude to her plan in public remarks on Monday and spell it out […]